Lysergic acid diethylamide (LSD), a synthetic psychedelic compound with potential therapeutic value for psychiatric disorders, is absorbed by the nematode Caenorhabditis elegans and acutely reduces its speed, an effect similar to that of endogenous serotonin. This response is partially mediated by the serotonergic receptors SER-1 and SER-4. The findings highlight the potential of C. elegans as a new experimental model for psychedelic research.
Lysergic Acid Diethylamide (LSD) is metabolized in the model organism Caenorhabditis elegans, producing a range of metabolites identified through ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry. The findings illuminate metabolic pathways and pharmacokinetics of LSD, demonstrating that C. elegans is a suitable system for studying psychedelic compound metabolism and supporting further research into therapeutic applications.
LSD is metabolized into several compounds in the roundworm Caenorhabditis elegans, as shown by ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry. The identified metabolites reveal specific metabolic pathways and offer insights into LSD's pharmacokinetics. The work demonstrates that C. elegans is a suitable model for studying psychedelic compound metabolism, providing a foundation for further research on LSD's therapeutic potential.